Patents by Inventor Cheng-Chi Chao
Cheng-Chi Chao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250019144Abstract: A holding device for a top-opening substrate container includes a holding assembly for pushing a substrate actuator disposed at a substrate to operate. The holding assembly includes a holding body and a pushing actuator. The pushing actuator includes a first guiding sloped surface for pressing against a second guiding sloped surface of an inner surface of a container door structure. The first guiding sloped surface causing corresponding pushing and displacement between the first guiding sloped surface and the second guiding sloped surface according to a supporting force of the container door structure. A pushing section is connected to the first guiding sloped surface, and capable of correspondingly pushing the substrate actuator to operate according to a level of the pushing and displacement of the first guiding sloped surface, such that the substrate actuator displaces substrates and stacks the substrates with another in layers.Type: ApplicationFiled: December 1, 2023Publication date: January 16, 2025Inventors: MING-CHIEN CHIU, YUNG-CHIN PAN, CHENG-EN CHUNG, WEI-CHIEN LIU, TZU-NING HUANG, TZU-CHI CHAO, TZU-WEI HUANG, CHIA-LIANG LIU
-
Patent number: 11976124Abstract: The present disclosure provides isolated monoclonal antibodies or an antigen-binding portion thereof that specifically bind to CD40 preferably human CD40 with high affinity, and that function as CD40 agonists. The disclosed invention also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies or portions of fusion proteins. Nucleic acid molecules encoding the antibodies of the disclosed invention, hybridoma, and methods for expressing the antibodies of the disclosed invention are also provided. Pharmaceutical compositions comprising the antibodies of the disclosed invention are also provided. This disclosure also provides methods for regulating humoral and cellular immune responses, as well as methods for treating cancer using an anti-CD40 agonist antibody of the disclosed invention.Type: GrantFiled: December 23, 2020Date of Patent: May 7, 2024Assignee: ABVISION, INC.Inventors: Chang-Hsin Chen, Gloria Zhang, Guochen Yan, Cheng-Chi Chao
-
Publication number: 20240084012Abstract: An isolated bispecific antibody or antigen-binding portion thereof includes a first chain which specifically binds to human PD-1(hPD-1) and blocks the interaction between hPD-1 and PD-L1, and a second chain which specifically binds to human CD47 and inhibits its interaction with SIRP-alpha, where the first chain and the second chain are coupled in a knob-in-hole format through their respective CH3 domain.Type: ApplicationFiled: December 31, 2021Publication date: March 14, 2024Inventors: Chun-Jen LIN, Cheng-Chi CHAO, Chang-Hsin Chen, Gloria Guohong ZHANG, Guochen YAN
-
Publication number: 20230042316Abstract: The present disclosure provides isolated monoclonal antibodies or antigen-binding portions thereof that specifically bind to CD47 preferably human CD47 with high affinity, and can enhance tumor-targeting immune response by therapeutically boosting the phagocytic function of macrophage for cancer treatment. The disclosure also provides antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies or portions of fusion proteins. Nucleic acid molecules encoding the antibodies of the disclosed invention and hybridoma are also provided. Pharmaceutical compositions comprising the antibodies of the disclosed invention are also provided. This disclosure also provides methods for regulating innate immune responses, as well as methods for treating cancer using an anti-CD47 antagonist antibody of the disclosed invention.Type: ApplicationFiled: November 20, 2020Publication date: February 9, 2023Inventors: Chun-Jen LIN, Cheng-Chi CHAO, Chang-Hsin CHEN, Gloria ZHANG, Guochen YAN
-
Publication number: 20210115149Abstract: The present disclosure provides isolated monoclonal antibodies or an antigen-binding portion thereof that specifically bind to CD40 preferably human CD40 with high affinity, and that function as CD40 agonists. The disclosed invention also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies or portions of fusion proteins. Nucleic acid molecules encoding the antibodies of the disclosed invention, hybridoma, and methods for expressing the antibodies of the disclosed invention are also provided. Pharmaceutical compositions comprising the antibodies of the disclosed invention are also provided. This disclosure also provides methods for regulating humoral and cellular immune responses, as well as methods for treating cancer using an anti-CD40 agonist antibody of the disclosed invention.Type: ApplicationFiled: December 23, 2020Publication date: April 22, 2021Inventors: Chang-Hsin CHEN, Gloria ZHANG, Guochen YAN, Cheng-Chi CHAO
-
Publication number: 20200017596Abstract: The present disclosure provides isolated monoclonal antibodies or an antigen-binding portion thereof that specifically bind to CD40 preferably human CD40 with high affinity, and that function as CD40 agonists. The disclosed invention also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies or portions of fusion proteins. Nucleic acid molecules encoding the antibodies of the disclosed invention, hybridoma, and methods for expressing the antibodies of the disclosed invention are also provided. Pharmaceutical compositions comprising the antibodies of the disclosed invention are also provided. This disclosure also provides methods for regulating humoral and cellular immune responses, as well as methods for treating cancer using an anti-CD40 agonist antibody of the disclosed invention.Type: ApplicationFiled: May 10, 2019Publication date: January 16, 2020Inventors: Cheng-Chi Chao, Chang-Hsin CHEN, Gloria ZHANG, Guochen YAN
-
Publication number: 20100239590Abstract: Novel methods and drug products for treating inflammatory joint diseases such as rheumatoid arthritis and associated arthritides are disclosed. The methods and products employ various serum markers of bone and cartilage metabolism or destruction, including cartilage oligomer matrix protein (COMP) and Receptor activator of NFB ligand (RANKL), as biomarkers to assess the effect of IL-17A antagonists on joint destruction in inflammatory joint diseases.Type: ApplicationFiled: June 20, 2008Publication date: September 23, 2010Inventors: Edward Paul Bowman, Cheng-Chi Chao, Shi-Juan Chen
-
Publication number: 20080241207Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.Type: ApplicationFiled: November 19, 2007Publication date: October 2, 2008Inventors: Y. Tom Tang, Ivan Labat, Radoje T. Drmanac, Nancy Mize, Mitsuo Nishikawa, Cheng-Chi Chao
-
Publication number: 20080241882Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes fro producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.Type: ApplicationFiled: November 16, 2007Publication date: October 2, 2008Inventors: Y. Tom Tang, Ivan Labat, Radoje T. Drmanac, Nancy Mize, Mitsuo Nishikawa, Cheng-Chi Chao
-
Patent number: 7319141Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.Type: GrantFiled: October 19, 2004Date of Patent: January 15, 2008Assignees: Kirin Beer Kabushiki Kaisha, Nuvelo, Inc.Inventors: Y. Tom Tang, Ivan Labat, Radoje T. Drmanac, Nancy K. Mize, Mitsuo Nishikawa, Cheng-Chi Chao
-
Patent number: 7317099Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from human fetal liver spleen, ovary, adult brain, lung tumor, spinal cord, cervix, ovary, endothelial cells, umbilical cord, lymphocyte, lung fibroblast, fetal brain, and testis. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.Type: GrantFiled: December 23, 2000Date of Patent: January 8, 2008Assignee: Kirin Pharma Kabushiki KaishaInventors: Ivan Labat, Y. Tom Tang, Radoje T. Drmanac, Chenghua Liu, Juhi Lee, Nancy K. Mize, John Childs, Cheng-Chi Chao
-
Publication number: 20060074044Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof the correspond to a novel human secreted stem cell growth factor-like polypeptide. These polypeptides comprise nucleic acid sequences isolated from cDNA libraries prepared from human fetal liver spleen, ovary, adult brain, lung tumor, spinal cord, cervix, ovary, endothelial cells, umbilical cord, lymphocyte, lung fibroblast, fetal brain, and testis. Other aspects of the invertion include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.Type: ApplicationFiled: November 18, 2005Publication date: April 6, 2006Applicant: NuveloInventors: Ivan Labat, Y. Tang, Radoje Drmanac, Chenghua Liu, Juhi Lee, Nancy Mize, John Childs, Cheng-Chi Chao
-
Method and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides
Publication number: 20050059073Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.Type: ApplicationFiled: October 19, 2004Publication date: March 17, 2005Inventors: Y. Tang, Ivan Labat, Radoje Drmanac, Nancy Mize, Mitsuo Nishikawa, Cheng-Chi Chao -
Patent number: 6824973Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.Type: GrantFiled: June 28, 2001Date of Patent: November 30, 2004Assignees: Kirin Beer Kabushiki Kaisha, Nuvelo Inc.Inventors: Y. Tom Tang, Ivan Labat, Radoje T. Drmanac, Nancy Mize, Mitsuo Nishikawa, Cheng-Chi Chao
-
Patent number: 6673904Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human and mouse secreted stem cell growth factor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from mouse bone marrow and human fetal liver spleen, ovary, adult brain, lung tumor, spinal cord, cervix, ovary, endothelial cells, umbilical cord, placental, lymphocyte, lung fibroblast, fetal brain, and testis. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.Type: GrantFiled: July 24, 2001Date of Patent: January 6, 2004Assignees: Kirin Beer Kabushiki Kaisha, Hyseq, Inc.Inventors: Mitsuo Nishikawa, Ivan Labat, Radoje T. Drmanac, Y. Tom Tang, Cheng-Chi Chao, Nancy Mize, John Childs
-
Patent number: 6667391Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein.Type: GrantFiled: January 16, 2001Date of Patent: December 23, 2003Inventors: Radoje T. Drmanac, Ivan Labat, Y. Tom Tang, Cheng-Chi Chao, Nancy K. Mize, John Childs
-
Publication number: 20030211987Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from human fetal liver spleen, ovary, adult brain, lung tumor, spinal cord, cervix, ovary, endothelial cells, umbilical cord, lymphocyte, lung fibroblast, fetal brain, and testis. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.Type: ApplicationFiled: February 3, 2003Publication date: November 13, 2003Inventors: Ivan Labat, Y Tom Tang, Radoje T Drmanac, Chenghua Liu, Juhi Lee, Nancy K Mize, John Childs, Cheng-Chi Chao
-
Publication number: 20030044792Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.Type: ApplicationFiled: June 28, 2001Publication date: March 6, 2003Inventors: Y. Tom Tang, Ivan Labat, Radoje T. Drmanac, Nancy Mize, Mitsuo Nishikawa, Cheng-Chi Chao
-
Publication number: 20030022825Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human and mouse secreted stem cell growth factor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from mouse bone marrow and human fetal liver spleen, ovary, adult brain, lung tumor, spinal cord, cervix, ovary, endothelial cells, umbilical cord, placental, lymphocyte, lung fibroblast, fetal brain, and testis. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.Type: ApplicationFiled: July 24, 2001Publication date: January 30, 2003Inventors: Mitsuo Nishikawa, Ivan Labat, Radoje T. Drmanac, Y. Tom Tang, Cheng-Chi Chao